No Data
Express News | Alto Neuroscience Receives Funding Award From Wellcome Trust to Accelerate Development of Alto-100 in Bipolar Depression Leveraging Precision Psychiatry Approach
Alto Neuroscience Completes Enrollment In ALTO-100 Phase 2b Study, Topline Results Expected In October
Express News | Alto Neuroscience Inc - to Report Topline Data of Study in Oct 2024
Express News | Alto Neuroscience Announces Enrollment Completion in Phase 2B Study of Alto-100 in Major Depressive Disorder
Rodman & Renshaw Initiates Alto Neuroscience(ANRO.US) With Buy Rating, Announces Target Price $43
Rodman & Renshaw analyst Elemer Piros initiates coverage on $Alto Neuroscience(ANRO.US)$ with a buy rating, and sets the target price at $43.According to TipRanks data, the analyst has a success rate
Alto Neuroscience Initiated at Buy by Rodman & Renshaw
No Data